Peter Cole

Dr. Peter Cole

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
TTThai Hoa Tran
Thai Hoa Tran
SLSylvie Langlois
Sylvie Langlois
CMCaroline Meloche
Caroline Meloche
MCMaxime Caron
Maxime Caron
PSPascal Saint-Onge
Pascal Saint-Onge
DSDaniel Sinnett
Daniel Sinnett
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognostic genetic alterations, many of which are cryptic by conventional cytogenetics. RNA sequencing (RNA-seq) is a powerful next-generation sequencing technology that can simultaneously identify cryptic gene rearrangements, sequence mutations and gene expression profiles in a single assay. We examined the feasibility and utility of incorporating RNA-seq into a prospective multicenter phase 3 clinical trial for children with newly diagnosed ALL. The Dana-Farber Cancer Institute ALL Consortium Protocol 16-001 enrolled 173 patients with ALL who consented to optional studies and had samples available for RNA-seq. RNA-seq identified at least 1 alteration in 157 patients (91%). Fusion detection was 100% concordant with results obtained from conventional cytogenetic analyses. An additional 56 gene fusions were identified by RNA-seq, many of which confer prognostic or therapeutic significance. Gene expression profiling enabled further molecular classification into the following B-cell ALL (B-ALL) subgroups: high hyperdiploid (n = 36), ETV6-RUNX1/-like (n = 31), TCF3-PBX1 (n = 7), KMT2A-rearranged (KMT2A-R; n = 5), intrachromosomal amplification of chromosome 21 (iAMP21) (n = 1), hypodiploid (n = 1), Philadelphia chromosome (Ph)-positive/Ph-like (n = 16), DUX4-R (n = 11), PAX5 alterations (PAX5 alt; n = 11), PAX5 P80R (n = 1), ZNF384-R (n = 4), NUTM1-R (n = 1), MEF2D-R (n = 1), and others (n = 10). RNA-seq identified 141 nonsynonymous mutations in 93 patients (54%); the most frequent were RAS-MAPK pathway mutations. Among 79 patients with both low-density array and RNA-seq data for the Philadelphia chromosome-like gene signature prediction, results were concordant in 74 patients (94%). In conclusion, RNA-seq identified several clinically relevant genetic alterations not detected by conventional methods, which supports the integration of this technology into front-line pediatric ALL trials. This trial was registered at www.clinicaltrials.gov as #NCT03020030.

1 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LVLynda M. Vrooman
Lynda M. Vrooman
TBTraci M. Blonquist
Traci M. Blonquist
KSKristen E. Stevenson
Kristen E. Stevenson
JSJeffrey G. Supko
Jeffrey G. Supko
SHSarah K. Hunt
Sarah K. Hunt
LSLewis B. Silverman
Lewis B. Silverman
PURPOSE: Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase), a novel pegylated asparaginase formulation with longer half-life, compared with the standard formulation pegaspargase. METHODS: Patients age 1 to ≤ 21 years with newly diagnosed ALL or lymphoblastic lymphoma were randomly assigned to intravenous pegaspargase or calaspargase, 2,500 IU/m2/dose. Patients received one induction dose. Beginning week 7, pegaspargase was administered every 2 week for 15 doses and calaspargase every 3 week for 10 doses (30 weeks). Serum asparaginase activity (SAA) (≥ 0.1 IU/mL considered therapeutic) was assessed 4, 11, 18, and 25 days after the induction dose and before each postinduction dose. RESULTS: Between 2012 and 2015, 239 eligible patients enrolled (230 ALL, nine lymphoblastic lymphoma); 120 were assigned to pegaspargase and 119 to calaspargase. After the induction dose, SAA was ≥ 0.1 IU/mL in ≥ 95% of patients on both arms 18 days after dosing. At day 25, more patients had SAA ≥ 0.1 IU/mL with calaspargase (88% v 17%; P ˂ .001). Postinduction, median nadir SAAs were similar (≥ 1.0 IU/mL) for both arms. Of 230 evaluable patients, 99% of pegaspargase and 95% of calaspargase patients achieved complete remission ( P = .12), with no difference in frequency of high end-induction minimal residual disease among evaluable patients with B acute lymphoblastic leukemia (B-ALL). There were no differences in frequencies of asparaginase allergy, pancreatitis, thrombosis, or hyperbilirubinemia. With 5.3 years median follow-up, 5-year event-free survival for pegaspargase was 84.9% (SE ± 3.4%) and 88.1% (± SE 3.0%) for calaspargase ( P = .65). CONCLUSION: Every 3-week calaspargase had similar nadir SAA, toxicity, and survival outcomes compared with every 2-week pegaspargase. The high nadir SAA observed for both preparations suggest dosing strategies can be further optimized.

Verified
Journal Article
Open access
PDF file
YPYongkyu Park
Yongkyu Park
NKNirajan Kc
Nirajan Kc
APAlysta Paneque
Alysta Paneque
PCPeter Cole
Peter Cole
Neurological damage is the pathological substrate of permanent disability in various neurodegenerative disorders. Early detection of this damage, including its identification and quantification, is critical to preventing the disease’s progression in the brain. Tau, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), as brain protein biomarkers, have the potential to improve diagnostic accuracy, disease monitoring, prognostic assessment, and treatment efficacy. These biomarkers are released into the cerebrospinal fluid (CSF) and blood proportionally to the degree of neuron and astrocyte damage in different neurological disorders, including stroke, traumatic brain injury, multiple sclerosis, neurodegenerative dementia, and Parkinson’s disease. Here, we review how Tau, GFAP, and NfL biomarkers are detected in CSF and blood as crucial diagnostic tools, as well as the levels of these biomarkers used for differentiating a range of neurological diseases and monitoring disease progression. We also discuss a biosensor approach that allows for the real-time detection of multiple biomarkers in various neurodegenerative diseases. This combined detection system of brain protein biomarkers holds significant promise for developing more specific and accurate clinical tools that can identify the type and stage of human neurological diseases with greater precision.

1 September 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
PCPeter Cole
Peter Cole
KMKathleen M McCarten
Kathleen M McCarten
QPQinglin Pei
Qinglin Pei
MSMenachem Spira
Menachem Spira
MMMonika L Metzger
Monika L Metzger
KKKara M Kelly
Kara M Kelly

1 June 2015 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MPMiguel-Angel Perales
Miguel-Angel Perales
ICIzaskun Ceberio
Izaskun Ceberio
PAPhilippe Armand
Philippe Armand
LBLinda J. Burns
Linda J. Burns
RCRobert Chen
Robert Chen
PCPaul A. Carpenter
Paul A. Carpenter
The role of hematopoietic cell transplantation (HCT) in the therapy of Hodgkin lymphoma (HL) in pediatric and adult patients is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are included and were reached unanimously by a panel of HL experts. Both autologous and allogeneic HCT offer a survival benefit in selected patients with advanced or relapsed HL and are currently part of standard clinical care. Relapse remains a significant cause of failure after both transplant approaches, and strategies to decrease the risk of relapse remain an important area of investigation.

7 October 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
MBMelissa A. Burns
Melissa A. Burns
APAndrew E. Place
Andrew E. Place
KSKristen E. Stevenson
Kristen E. Stevenson
AGAlejandro Gutiérrez
Alejandro Gutiérrez
SFSuzanne Forrest
Suzanne Forrest
LSLewis B. Silverman
Lewis B. Silverman
Background/objectives: While outcomes for pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) are favorable, there are few widely accepted prognostic factors, limiting the ability to risk stratify therapy.Design/methods: Dana‐Farber Cancer Institute (DFCI) Protocols 05‐001 and 11‐001 enrolled pediatric patients with newly diagnosed B‐ or T‐ALL from 2005 to 2011 and from 2012 to 2015, respectively. Protocol therapy was nearly identical for patients with T‐ALL (N = 123), who were all initially assigned to the high‐risk arm. End‐induction minimal residual disease (MRD) was assessed by reverse transcription polymerase chain reaction (RT‐PCR) or next‐generation sequencing (NGS), but was not used to modify postinduction therapy. Early T‐cell precursor (ETP) status was determined by flow cytometry. Cases with sufficient diagnostic DNA were retrospectively evaluated by targeted NGS of known genetic drivers of T‐ALL, including Notch, PI3K, and Ras pathway genes.Results: The 5‐year event‐free survival (EFS) and overall survival (OS) for patients with T‐ALL was 81% (95% CI, 73‐87%) and 90% (95% CI, 83‐94%), respectively. ETP phenotype was associated with failure to achieve complete remission, but not with inferior OS. Low end‐induction MRD (<10−4) was associated with superior disease‐free survival (DFS). Pathogenic mutations of the PI3K pathway were mutually exclusive of ETP phenotype and were associated with inferior 5‐year DFS and OS.Conclusions: Together, our findings demonstrate that ETP phenotype, end‐induction MRD, and PI3K pathway mutation status are prognostically relevant in pediatric T‐ALL and should be considered for risk classification in future trials. DFCI Protocols 05‐001 and 11‐001 are registered at www.clinicaltrials.gov as NCT00165087 and NCT01574274, respectively.